The US government plans 100% tariffs on generic medicines imported into the US starting in August 2028, rising to 200% in August 2029 unless production is relocated to the United States, a move that would hit India’s roughly $30 billion pharma sector which now supplies about 47% of US generic prescriptions and 38% of US pharma exports.

Patented, branded, or innovative drugs would remain subject to the existing policy, with the tariffs applying specifically to generics and API-related products.

A two-year grace period is designed to give manufacturers time to relocate production, plan investments, and adjust supply chains before the tariffs take full effect.

The report notes the information is evolving and cites ongoing updates from sources such as Die Zeit, AFP, and dpa.

Market context is mentioned, including reference to Johnson & Johnson in commentary, though not central to the policy itself.

Concomitant market context shows oil prices rising amid Middle East tensions, with Brent around $94 and WTI near $87, as major indices in Europe and Asia display mixed moves.

Investors are watching for AI-related demand and upcoming earnings from major tech firms, with mentions of Alphabet, Intel, Microsoft, and Meta.

Access to the full analysis is behind a STAT+ paywall, limiting exclusive insights.

The impact of the tariffs will depend on specifics like exemptions, covered products, transitional rules, and implementation, potentially affecting market dynamics more in the medium term than immediately.

The tariff discussion sits within a broader context of ongoing trade policy, supply-chain considerations, and past tariff actions and court rulings through 2025–2026.

Industry voices emphasize leveraging cost, quality, and scale while monitoring policy developments, since tariffs could change with political shifts.